


NOTICE TO THE BAR

MULTICOUNTY LITIGATION – CONCLUSION OF PROPECIA® LITIGATION CENTRALIZED MANAGEMENT AND HANDLING AS MCL

In accordance with the provisions of Court Rule 4:38A and Directive #02-19, "Multicounty Litigation Guidelines and Criteria for Designation (Revised)," a previous Notice to the Bar sought comments on the recommendation of Superior Court Judge Bruce Kaplan for conclusion of the Propecia® litigation centralized management and handling as a Multicounty Litigation. This Notice is to advise that the Supreme Court, after considering the recommendation and having received no comments objecting to the conclusion, has concluded the centralized management of all pending and future state-court litigation involving use of the drug Propecia®.

Published with this Notice is the Court's Order, which also is posted with this Notice on the Judiciary's Internet Website at (www.njcourts.gov) in the MCL Information Center <http://www.njcourts.gov/attorneys/mcl/index.html>.

Questions concerning the Court's conclusion of the MCL designation of the Propecia® Litigation may be directed to Melissa A. Czartoryski, Chief, Civil Court Programs, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone (609) 815-2900 ext. 54900; email address: Melissa.Czartoryski@njcourts.gov.



Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: September 17, 2021

SUPREME COURT OF NEW JERSEY

It is ORDERED that the Supreme Court's Order of March 7, 2012 that designated all New Jersey state court litigation involving Propecia for centralized management and assignment to Middlesex County Superior Court for handling by the mass tort (now multicounty litigation) judge in that vicinage, and the intervening reassignment orders dated March 29, 2017, July 24, 2017, and January 25, 2021, are hereby concluded.

For the Court,



Chief Justice

Dated: September 7, 2021